Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial

Moderna, Merck cancer vaccine shows initial late-stage melanoma data Skip Navigation Markets Pre-Markets U.S. Markets Currencies Prediction Markets Cryptocurrency Futures & Commodities Bonds Funds & ETFs Business Economy Finance Health & Science Media Real Estate Energy Climate Transportation Investigations Industrials Retail Wealth Sports Life Small Business Investing Personal Finance Fintech Financial Advisors Options Action ETF Street Buffett Archive Earnings Trader Talk Tech Cybersecurity AI Enterprise Internet Media Mobile Social Media CNBC Disruptor 50 Tech Guide Politics & Policy White House Policy Defense Congress Expanding Opportunity Video Latest Video Full Episodes Livestream Live Audio Live TV Schedule CNBC Podcasts CEO Interviews CNBC Documentaries Digital Originals Watchlist Investing Club Trust Portfolio Analysis Trade Alerts Meeting Videos Homestretch Jim's Columns Education Subscribe PRO Pro News Josh Brown Mike Santoli Calls of the Day My Portfolio Livestream Full Episodes Stock Screener Market Forecast Options Investing Chart Investing Subscribe Livestream Menu Make It select USA INTL Livestream Search quotes, news & videos Livestream Watchlist SIGN IN Create free account Markets Business Investing Tech Politics & Policy Video Watchlist Investing Club PRO Livestream Menu Health and Science Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial Published Wed, Aug 19 2026 6:46 AM EDT Updated 15 Min Ago Annika Kim Constantino @annikakimc WATCH LIVE Key Points An experimental personalized cancer vaccine from Merck and Moderna showed positive initial results in its first-ever late-stage trial. The combination regimen met the main study goal of significantly extending the time patients lived without their melanoma returning, compared with Keytruda alone, and also reduced the risk of the cancer spreading to distant parts of the body. The initial data suggest that the combo could serve as a new treatment option for the deadliest form of skin cancer, and validate a new personalized treatment approach. In this article MRK MRNA Follow your favorite stocks CREATE FREE ACCOUNT Mike Blake | Reuters An experimental personalized cancer vaccine from Merck and Moderna showed positive initial results in its first-ever late-stage trial, the companies announced Wednesday, bringing them one step closer to filing for approval of the treatment option. The mRNA-based shot in combination with Merck's immunotherapy Keytruda met key goals in the phase three trial in more than 1,100 patients with higher-risk or advanced melanoma whose detectable cancer had been completely removed through surgery. Bu özet bilgilendirme amaçlıdır, yatırım tavsiyesi değildir. — hisseonlinebot